利福平暴露与临床基线协变量对肺结核治疗反应的影响
本研究在南非Worcester招募402例药物敏感肺结核初治患者,每周收集痰标本12周,用MGIT管量化细菌载量得TTP,非线性混合效应模型分析利福平暴露等协变量对TTP轨迹的影响。结果显示较高利福平AUC与TTP更快纵向变化相关,肺空洞和年龄较大与较慢变化相关,治疗前12周TTP变化较慢与6个月治疗失败相关。
要点
- 较高利福平血浆AUC与药物敏感肺结核患者痰菌清除更快相关。
- 基线涂片分级高和肺空洞降低基线TTP,肺空洞和年龄较大使TTP变化更慢。
- 治疗前12周TTP变化较慢与6个月治疗失败相关。
核心结论
- 利福平血浆暴露在标准剂量方案内仍影响药物敏感肺结核的痰菌清除和治疗结局。
研究设计与样本
- 在南非Worcester招募药物敏感肺结核初治患者,每周收集痰标本共12周,用MGIT管量化细菌载量得TTP。
- 共纳入402例患者,60%为男性,中位年龄37岁(四分位距26-48)。
- 采用非线性混合效应模型描述纵向TTP,评估利福平暴露和其他参与者特征作为协变量。
主要发现
- 6个月时90%患者治疗成功(治愈或完成治疗),3%治疗失败,2%死亡,1%转诊,4%失访。
- 基线涂片分级和肺空洞降低基线TTP。
- 较高利福平浓度AUC与TTP更快纵向变化相关,肺空洞和年龄较大与较慢纵向变化相关。
- 治疗前12周TTP变化较慢与6个月治疗失败相关。
临床怎么用
- 对药物敏感肺结核患者,可关注利福平血浆暴露水平以优化痰菌清除。
- 治疗前12周TTP变化较慢可能提示6个月治疗失败风险,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quantitative markers of tuberculosis disease burden are essential for assessing treatment response and optimizing therapeutic strategies. This study evaluated the impact of antimicrobial plasma drug levels on time-to-positivity (TTP) trajectories in patients with drug-susceptible tuberculosis and explored the relationship between bacillary clearance and treatment outcomes. METHODS: Patients with drug susceptible pulmonary tuberculosis initiating treatment were recruited in Worcester, South Africa. Weekly sputum samples were collected for 12 weeks, with bacterial load quantified using Mycobacterial Growth Indicator Tubes, yielding TTP. Nonlinear mixed-effects modeling was used to empirically describe longitudinal TTP, assessing rifampicin exposure and other participant characteristics as covariates. TTP trajectories were stratified by treatment outcomes to identify trends between change in TTP and outcome. RESULTS: A total of 402 participants were included, of whom 60% were male. Median age was 37 years (interquartile ratio 26-48) and 90% had successful treatment outcomes (were cured or completed treatment) at 6 months with 3% who experienced treatment failure, 2% died, 1% transferred, and 4% were lost to follow-up. Baseline smear grade and lung cavitation decreased baseline TTP. Higher rifampicin concentration area under the curve was associated with faster longitudinal change in TTP, whereas lung cavitation and older age were associated with slower longitudinal change. Furthermore, slower change in TTP during the first 12 weeks of treatment was linked to treatment failure at 6 months. CONCLUSIONS: Our findings highlight the role of rifampicin plasma exposure in optimizing bacillary clearance and improving treatment outcomes, even within standard dosing regimens for drug-susceptible tuberculosis.
引用
- Wijk M, Denti P, Gausi K, et al. Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment. Clin Infect Dis. 2026. PMID: 41133922. doi:10.1093/cid/ciaf586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。